https://compepharma.com/story/o-a848e35fc89eb7c8CompePharmaen2026-11-13Medline details repair and replace programme for recalled beds, rails, mattresses and accessorieshttps://compepharma.com/story/c-bc5e9c020181bcf41273CompePharmaen2026-11-13BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6Mhttps://compepharma.com/story/c-ea78be4680dbcaae406fCompePharmaen2026-11-13IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0Mhttps://compepharma.com/story/c-7bac75cd441265042b6dCompePharmaen2026-11-13Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 INDhttps://compepharma.com/story/c-746ec119769afbeff900CompePharmaen2026-11-13IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approachhttps://compepharma.com/story/c-752198cf933dd31cbe30CompePharmaen2026-11-13Imricor starts US launch of NorthStar iMR system after paediatric FDA clearanceshttps://compepharma.com/story/c-0db254b4ba607ba4a8ceCompePharmaen2026-11-13Helus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation riseshttps://compepharma.com/story/c-240bad34c7d3adf3d7f0CompePharmaen2026-11-13Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PHhttps://compepharma.com/story/c-811777c899b2328f0396CompePharmaen2026-11-13IM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israelhttps://compepharma.com/story/c-74d9e16e8d3418c8964dCompePharmaen2026-11-13MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer firsthttps://compepharma.com/story/c-53f4dc62f13b5a8c210bCompePharmaen2026-11-13Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trialhttps://compepharma.com/story/c-63f117ca441190f2bc08CompePharmaen2026-11-13DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensinghttps://compepharma.com/story/c-62d2fccb41f07c07636fCompePharmaen2026-11-13FDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapyhttps://compepharma.com/story/c-3dce2dfc57e64b3f9034CompePharmaen2026-11-13BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLChttps://compepharma.com/story/c-a866513e69da3de43cfaCompePharmaen2026-11-13FDA grants NeOnc Type B meeting on accelerated approval path for intranasal NEO100https://compepharma.com/story/c-643c892242ede9720cd7CompePharmaen2026-11-13Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027https://compepharma.com/story/c-cc234b08df4c9379a0f6CompePharmaen2026-11-13Cingulate nearly done with manufacturing fixes for ADHD drug CTx-1301 ahead of NDA resubmissionhttps://compepharma.com/story/c-a01468a8d547eb587ac1CompePharmaen2026-11-13Bluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027https://compepharma.com/story/c-1555764ceb6e93a65141CompePharmaen2026-11-13CHMP backs Cosentyx for adolescents aged 12+ with moderate-to-severe hidradenitis suppurativahttps://compepharma.com/story/n-a084e76082d9cdfceeb3CompePharmaen2026-11-13Philips recalls Azurion 7 M20 over software faults that can halt imaging or stand movementhttps://compepharma.com/story/c-f3e0716472f742a8c49fCompePharmaen2026-11-13Valneva: 94% of adults still seroresponders five years after single IXCHIQ dosehttps://compepharma.com/story/c-115315367dee320ae6c1CompePharmaen2026-11-13Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patienthttps://compepharma.com/story/c-baf682c3549a12119332CompePharmaen2026-11-13Lifeward Q3 revenue falls 12% as AlterG grows and ReWalk moves to channel partnershttps://compepharma.com/story/c-1de08a8e1012cfa96ffaCompePharmaen2026-11-13GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stagehttps://compepharma.com/story/c-2a3377d79610c37dae39CompePharmaen2026-11-13Medicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filinghttps://compepharma.com/story/c-3125da9dfa5315e8ebfeCompePharmaen2026-11-13FDA lifts ARD-101 clinical hold in Prader-Willi; Aardvark to run open-label trialhttps://compepharma.com/story/c-225c80f18fc349ac959eCompePharmaen2026-11-13MetaVia details DA-1726 interim data and vanoglipel MASH plans in investor deckhttps://compepharma.com/story/c-27113b583630e4846173CompePharmaen2026-11-13Fortress Biotech Q3 revenue rises 9% to $19.2M as Oaktree facility is repaidhttps://compepharma.com/story/c-c438ff045d1b6a2f48a1CompePharmaen2026-11-13Benitec: all treated OPMD patients responded to BB-301; pivotal trial planned for mid-2027https://compepharma.com/story/c-1b10546a3d2fe5bddd6aCompePharmaen2026-11-13TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AMLhttps://compepharma.com/story/c-71aedd335b6551140dacCompePharmaen2026-11-13Milestone cuts costs by about 30% as CARDAMYST posts $1.0M third-quarter saleshttps://compepharma.com/story/c-ed0b021ed68bb9670d47CompePharmaen2026-11-13Biofrontera wins FDA nod for Ameluz in superficial BCC as Q3 revenue rises 30%https://compepharma.com/story/c-cf21e4b34b6b724104a6CompePharmaen2026-11-13CHMP backs Roche's Gazyvaro as add-on therapy for autoantibody-positive lupushttps://compepharma.com/story/c-7c54272a35f63d3b90daCompePharmaen2026-11-13CHMP recommends Roche's Gazyvaro as add-on therapy for autoantibody-positive lupushttps://compepharma.com/story/c-51c6d6972259e3278606CompePharmaen2026-11-13Quantum BioPharma reports Q3 equity up 91% as Lucid-MS Phase 2 start-up advanceshttps://compepharma.com/story/c-648dd786dc5a5b6c5acbCompePharmaen2026-11-13Grown Rogue posts $11.0M Q3 revenue, books $8.9M net loss on Illinois dealhttps://compepharma.com/story/c-d906fda6c67e307c7010CompePharmaen2026-11-13Bavarian Nordic Q3 revenue flat at DKK 1,805m as Travel Health grows 22%https://compepharma.com/story/o-94da0395c997918eCompePharmaen2026-11-13Florida man pleads guilty to $42M Medicare fraud over braces and cancer genetic testshttps://compepharma.com/story/o-096b4d0ffe6919f6CompePharmaen2026-11-12Game Changer Products recalls all lots of 10 Day Forecast capsules over hidden sildenafilhttps://compepharma.com/story/n-88b418a49a512b2b4d20CompePharmaen2026-11-12Health Canada lists Type II recall of Terumo BCT Spectra Optia software version 12.1https://compepharma.com/story/c-b2f29ffff72743f255c8CompePharmaen2026-11-12Mesoblast chair says firm is pivoting to commercial execution as Ryoncil earns about US$115mhttps://compepharma.com/story/c-a60c6aebc011f3c0d3adCompePharmaen2026-11-12Mesoblast reports US$115M first full-year Ryoncil revenue as late-stage programmes advancehttps://compepharma.com/story/c-d865dc2fa63ab29c064bCompePharmaen2026-11-12Mesoblast appoints interim COO as it prepares rexlemestrocel-L filings in heart failure and back painhttps://compepharma.com/story/c-b6ae69abf8223b2033abCompePharmaen2026-11-12NOAA pushes TMC deep-seabed mining certification decision to mid-December as company posts $28.4M Q3 losshttps://compepharma.com/story/c-47020bdad72e19c27472CompePharmaen2026-11-12Cardiff Oncology: onvansertib Phase 2 PFS not yet reached; Phase 3 could start Q1 2027https://compepharma.com/story/c-dddecbb45238b9d72ec7CompePharmaen2026-11-12Quantum Biopharma narrows nine-month net loss to $17.3M as cash and digital assets risehttps://compepharma.com/story/c-0c578afd739040a40f36CompePharmaen2026-11-12Bio Green Med Solution Q3 fire-safety sales reach $454,000 as net loss narrowshttps://compepharma.com/story/c-815af78f89006d4c2e15CompePharmaen2026-11-12Elite Pharmaceuticals second-quarter revenue rises 10.4% to $40.1m on own-label amphetamine and naltrexonehttps://compepharma.com/story/c-e724ca51285ecb51de60CompePharmaen2026-11-12Cibus reports Latin American rice trait trials succeeded as biofragrance manufacturing beginshttps://compepharma.com/story/c-ee26ac8460a454750fd7CompePharmaen2026-11-12Obsidian's amsoki-cel shows 67% response rate in resistant melanoma as registration cohort enrolshttps://compepharma.com/story/c-536ea263de05ef12cac7CompePharmaen2026-11-12CapsoVision Q3 revenue rises to $3.6M as FDA-cleared AI Highlights tool launches in UShttps://compepharma.com/story/c-1207ce0dc47e6dcf96acCompePharmaen2026-11-12Talphera asks FDA to let NEPHRO CRRT enrolment close early for nafamostat PMAhttps://compepharma.com/story/c-479e9cbd5cf0948a4ccbCompePharmaen2026-11-12Fractyl's Revita meets six-month REMAIN-1 endpoint as company plans De Novo filing and cuts 45% of staffhttps://compepharma.com/story/c-49b927bdf83963959ecfCompePharmaen2026-11-12CytoSorbents reaches operating cash flow breakeven in Q3 as revenue edges up 3%https://compepharma.com/story/c-ac71ce90ecaeb313ad2dCompePharmaen2026-11-12Nuwellis files 510(k) to extend Aquadex to children from 5 kg as losses narrowhttps://compepharma.com/story/c-83cfee75bd7ae5d4ca4bCompePharmaen2026-11-12Verrica reports record Q3 YCANTH sales of $5.7M as first common warts Phase 3 enrolment completeshttps://compepharma.com/story/c-14b30e205c84efcf0cabCompePharmaen2026-11-12NeuroPace slashes 2026 revenue guidance after weak third quarter, files Remote Care PMA supplementhttps://compepharma.com/story/c-561bcd9aad4f3a6c1d0bCompePharmaen2026-11-12Quantum BioPharma extends Unbuzzd loan to 2027 and delists Class B shares from CSEhttps://compepharma.com/story/c-ce324f2d6f751bf8f316CompePharmaen2026-11-12ProKidney Keeps PROACT 1 eGFR Slope Readout on Track for Q2 2027https://compepharma.com/story/c-140fdf036c559ad15bfaCompePharmaen2026-11-12Intellia's CRISPR therapy lonvo-z for hereditary angioedema gets FDA priority review, March 2027 goal datehttps://compepharma.com/story/c-b4c844bb4be673a7d9beCompePharmaen2026-11-12Nektar starts all three Phase 3 atopic dermatitis trials of rezpegaldesleukinhttps://compepharma.com/story/c-0fb0cd830d55c25e0428CompePharmaen2026-11-12Azitra's ATR-04 Clears Cohort 1 Safety Review, Widening Eligibility to MEK Inhibitor Rashhttps://compepharma.com/story/c-9d174b63b1239a8e37e1CompePharmaen2026-11-12BlossomHill agrees 50 mg twice-daily dose of BH-30643 with FDA ahead of pivotal trialhttps://compepharma.com/story/c-d98a81b53a1d7163e66cCompePharmaen2026-11-12Eledon wins FDA IND clearance and Fast Track for tegoprubart as Phase 3 kidney trial nearshttps://compepharma.com/story/c-219ec7b42f6d1609da55CompePharmaen2026-11-12Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives reviewhttps://compepharma.com/story/c-dc187b08a56638c9cca0CompePharmaen2026-11-12Erasca's pan-RAS glue ERAS-0015 wins FDA Fast Track for pancreatic cancerhttps://compepharma.com/story/c-da4d1ce426d6a682bb07CompePharmaen2026-11-12Ensysce closes Cy Biopharma deal as UK regulator seeks more data on CY200 trialhttps://compepharma.com/story/c-671afb5690210fbfc864CompePharmaen2026-11-12FDA grants Breakthrough Therapy status to Armata's phage cocktail AP-SA02 for S. aureus bacteremiahttps://compepharma.com/story/c-4b5fb7f472d86815ac62CompePharmaen2026-11-12Immix reports 89% complete response for CAR-T NXC-201 in AL amyloidosis, targets 2027 BLAhttps://compepharma.com/story/c-40258db5535e8f05a2a4CompePharmaen2026-11-12Cellectis nine-month revenue falls to $14.8M as R&D spend climbs and equity turns negativehttps://compepharma.com/story/c-88564929fbb468d7d489CompePharmaen2026-11-12Rocket Pharmaceuticals reports FDA alignment on RP-A501 pivotal Danon trial design in Q3 updatehttps://compepharma.com/story/c-78c13631c8f3b4f238d2CompePharmaen2026-11-12Candel delays prostate cancer BLA to mid-2027 as it refines assay with FDAhttps://compepharma.com/story/c-8045154a48f3c8c1369aCompePharmaen2026-11-12Arrowhead files plozasiran sNDA for severe hypertriglyceridemia under FDA STAR pilothttps://compepharma.com/story/c-aea6ad9aea21aca1429cCompePharmaen2026-11-12Praxis Precision Medicines sets peak sales view above $20bn at New York Investor Dayhttps://compepharma.com/story/c-40fd2c6413cf93d3509bCompePharmaen2026-11-12Azora Therapeutics, formerly Adial, reports Q3 loss of $64.6m as AT177 heads for 2027 INDhttps://compepharma.com/story/c-9fbcb5e48e5bf346317fCompePharmaen2026-11-12FDA clears InspireMD's CGuard Prime stent for transcarotid artery revascularisation via PMA supplementhttps://compepharma.com/story/c-1e1959b26c4f4d981030CompePharmaen2026-11-12BioCardia nears Japan filing for CardiAMP and plans Helix De Novo request in Q1 2027https://compepharma.com/story/c-40999777fb2a9dd43f37CompePharmaen2026-11-12Anaptys reports quarterly results as Jemperli sales rise 29% and GSK dispute ruling nearshttps://compepharma.com/story/n-aefa36d63542f0ec6dfbCompePharmaen2026-11-12Health Canada lists Type II recall of Beaver-Visitec Mini Blades over seal integrity concernhttps://compepharma.com/story/n-afd83dc6855e47380a10CompePharmaen2026-11-12Health Canada lists Type II recall of Siemens MAGNETOM Flow.Elite MRI software hotfixhttps://compepharma.com/story/n-31168d7f442cb250ec9dCompePharmaen2026-11-12Health Canada flags cybersecurity flaw in GE HealthCare's Centricity Universal Viewer in Type II recallhttps://compepharma.com/story/c-bb5edeae012cd1a136f5CompePharmaen2026-11-12Novartis reports 52-week Phase III data for Rhapsido in chronic inducible urticariahttps://compepharma.com/story/n-2f67e198c73eb8ca6012CompePharmaen2026-11-12Health Canada lists Type I recall of Cardinal Health procedure trays over BD Alaris infusion setshttps://compepharma.com/story/n-0ccd5e082e46a06d6d05CompePharmaen2026-11-12Health Canada lists Type II recall of Siemens MAGNETOM Flow.Elite MRI software hotfixhttps://compepharma.com/story/c-60ae4a0211c3cf915ec2CompePharmaen2026-11-12DBV reports further VITESSE Phase 3 data on peanut patch in children aged 4-7https://compepharma.com/story/c-36240d6f085c113e5017CompePharmaen2026-11-12Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stagehttps://compepharma.com/story/c-0dc8aa11297bf001252eCompePharmaen2026-11-12Medicare begins paying $1,938.01 per EsoGuard test as Lucid reports record October volumehttps://compepharma.com/story/c-10969abbadfc99adfe62CompePharmaen2026-11-12SeaStar Medical pushes NEUTRALIZE-AKI enrolment completion to mid-2027 as Quelimmune revenue climbshttps://compepharma.com/story/c-ff3eaf775f2105df4223CompePharmaen2026-11-12CorMedix Q3 revenue hits $54.5M as DefenCath sales fall after TDAPA endshttps://compepharma.com/story/c-fbb27cbc7273efbdd510CompePharmaen2026-11-12PolyPid's D-PLEX100 under FDA priority review with 28 November goal date; EMA validates MAAhttps://compepharma.com/story/c-0fa18c44a80ea7f2d1e9CompePharmaen2026-11-12Theriva Sells SYN-004 Antibiotic-Enzyme Assets to Biossil Labs for $350,000 Upfronthttps://compepharma.com/story/c-4028e1a96d4df402300fCompePharmaen2026-11-12ProMIS flags Q1 2027 topline data for Alzheimer's antibody PMN310 in Phase 1bhttps://compepharma.com/story/c-f6d1d79b12a4f457fd1cCompePharmaen2026-11-12Oncolytics and Coherus agree toripalimab supply for pelareorep anal cancer studyhttps://compepharma.com/story/c-85a8df4c74070d6dacb2CompePharmaen2026-11-12Sagimet doses first US Phase 3 acne patient with denifanstat, extends cash runway to mid-2029https://compepharma.com/story/c-bc7b4caa59f5b293fd15CompePharmaen2026-11-12MeiraGTx to file bota-vec MAA with EMA in December, FDA BLA to follow in Q1 2027https://compepharma.com/story/c-76a756f7c6650ea46765CompePharmaen2026-11-12Ascendis Q3 product revenue rises 89% to €366M as CHMP backs TransCon CNPhttps://compepharma.com/story/c-322a2030d479df9972aaCompePharmaen2026-11-12Grace Therapeutics starts second US CMO transfer for GTx-104 after FDA complete responsehttps://compepharma.com/story/c-ebe7e8e9f7b19ac0b99fCompePharmaen2026-11-12SpyGlass Pharma buys lens maker AVS and reports four-year glaucoma implant datahttps://compepharma.com/story/c-e8bccfa423828b8d0b68CompePharmaen2026-11-12Vivani reports $7.3M Q3 loss as semaglutide implant data nearhttps://compepharma.com/story/c-21c42a05162e490e676bCompePharmaen2026-11-12Kyverna completes rolling BLA for miv-cel CAR-T in stiff person syndromehttps://compepharma.com/story/c-f85f1e6c3919e8231854CompePharmaen2026-11-12Monopar nears completion of rolling NDA for ALXN1840 in Wilson disease as Q3 loss hits $6.2mhttps://compepharma.com/story/c-35855c6fb21261f82d14CompePharmaen2026-11-12Taysha completes TSHA-102 PPQ campaign and reports no severe treatment-related SAEs in 33 patientshttps://compepharma.com/story/c-a8a3a6d3a74391c1d321CompePharmaen2026-11-12Ascendis Q3 product revenue reaches €366M as CHMP backs TransCon CNP in achondroplasiahttps://compepharma.com/story/c-1153b0b25117a2151f04CompePharmaen2026-11-12ProQR cash rises to about €103.0M in Q3 2026 interim accountshttps://compepharma.com/story/c-1894d85ae7645b6e7c6eCompePharmaen2026-11-12Quantum BioPharma shareholders approve all meeting items; insider share placement closeshttps://compepharma.com/story/c-0d740df0c997bb47a30dCompePharmaen2026-11-12Auditor flags going-concern doubt at Marea and M2 despite $75.3M cashhttps://compepharma.com/story/c-c1584475ccc063cf5fdaCompePharmaen2026-11-12MediWound Q3 revenue falls to $3.6M as EscharEx VALUE trial nears full enrolmenthttps://compepharma.com/story/c-c0395c1368c19f26603eCompePharmaen2026-11-12Alvotech nine-month revenue falls 23% as FDA accepts AVT80 filing and clears Simlandi processhttps://compepharma.com/story/c-e7badd5e2df365374377CompePharmaen2026-11-12BioHarvest Sciences posts Q3 net loss of $3.3M as revenue falls to $7.9Mhttps://compepharma.com/story/c-0ee7fb5ec0c6001f0cc1CompePharmaen2026-11-12Satellos amends BASECAMP endpoint for forazapadin in DMD; FSHD trial cleared by FDA and Health Canadahttps://compepharma.com/story/c-21dfe36b73c6123cc677CompePharmaen2026-11-12Pelthos Q3 Zelsuvmi revenue rises 114% to $15.2M as Castle Creek merger nearshttps://compepharma.com/story/c-057d81d92f12615fa1ecCompePharmaen2026-11-12Lakefront Biotherapeutics reports €13.9M nine-month profit and approves second €50M buybackhttps://compepharma.com/story/c-27f333510948e7eedf70CompePharmaen2026-11-12Kiora licenses Senju's oral calpain inhibitor KIO-401 for retinal artery occlusion, seeks FDA meetinghttps://compepharma.com/story/c-b732d5d1baead7153fb0CompePharmaen2026-11-12Can-Fite reports piclidenoson lowered kidney protein-loss marker in preclinical Lowe syndrome workhttps://compepharma.com/story/c-9c5da71061a5049b590aCompePharmaen2026-11-12Traws Pharma: ratutrelvir matches Paxlovid on symptom resolution in final Phase 2a COVID-19 datahttps://compepharma.com/story/c-445e5ebb0a92576fe2d9CompePharmaen2026-11-12Yarrow Bioscience says $268.9M cash funds Graves' disease antibody trial into 2030https://compepharma.com/story/c-ca241bac87f7e8216aa9CompePharmaen2026-11-12FDA grants priority review to Belite Bio's tinlarebant for Stargardt disease; PDUFA date 12 February 2027https://compepharma.com/story/c-21f39f71a6a4380b71d4CompePharmaen2026-11-12Altimmune reports Q3 loss of $31.6m as pemvidutide MASH Phase 3 stays on trackhttps://compepharma.com/story/c-b65064abc272735ca619CompePharmaen2026-11-12Pharvaris Gets April 2027 FDA Decision Date for Oral HAE Therapy Deucrictibanthttps://compepharma.com/story/c-0fd2a661947b1b4b51c6CompePharmaen2026-11-12UK CMA raises vehicle refinish concerns in Phase 1 review of AkzoNobel-Axalta mergerhttps://compepharma.com/story/c-6db4caa9356897be89dfCompePharmaen2026-11-12Charlotte's Web narrows Q3 operating loss as California hemp limits cut revenue 18%https://compepharma.com/story/c-684e89165056a38e2340CompePharmaen2026-11-12EyePoint ends wet AMD programme after DURAVYU Phase 3 misses, cuts 53% of staffhttps://compepharma.com/story/c-51e7b8680bda0bf7b0a3CompePharmaen2026-11-12enGene plans to start detalimogene BLA by end-2026 after FDA pre-BLA meetinghttps://compepharma.com/story/c-3bb734488a4d19b4b1ccCompePharmaen2026-11-12Gedeon Richter licenses estetrol combination rights to Eli Lilly in worldwide dealhttps://compepharma.com/story/c-5f01ff6ebda0ed900fe8CompePharmaen2026-11-12Santhera names SteinCares exclusive Latin American distributor for Duchenne drug Agamreehttps://compepharma.com/story/o-b7ca1c70880977a1CompePharmaen2026-11-12MHRA flags Class 4 packaging defect on Star Pharmaceuticals enalapril/hydrochlorothiazide tabletshttps://compepharma.com/insights/2026-11-14-view-revenue-is-not-the-scoreboard-earnings-season-rewards-what-each-dollar-is-worthCompePharmaen2026-11-14Revenue is not the scoreboard: earnings season rewards what each dollar is worthhttps://compepharma.com/insights/2026-11-14-biocryst-s-q3-caremed-inventory-build-flatters-orladeyo-as-profits-roughly-doublCompePharmaen2026-11-14BioCryst's Q3: CareMed inventory build flatters ORLADEYO as profits roughly double and guidance riseshttps://compepharma.com/insights/2026-11-14-cormedix-s-heron-asset-buy-adds-four-marketed-drugs-and-about-150m-in-revenueCompePharmaen2026-11-14CorMedix's Heron Asset Buy Adds Four Marketed Drugs and About $150M in Revenuehttps://compepharma.com/insights/2026-11-14-view-compepharma-view-strong-quarters-narrow-foundationsCompePharmaen2026-11-14CompePharma View: Strong quarters, narrow foundationshttps://compepharma.com/insights/2026-11-14-richter-gives-lilly-estetrol-combination-rights-keeping-a-us-option-on-fylrevyCompePharmaen2026-11-14Richter Gives Lilly Estetrol Combination Rights, Keeping a US Option on FYLREVYhttps://compepharma.com/insights/2026-11-14-transmedics-q3-revenue-up-41-but-opex-growth-squeezes-margins-and-epsCompePharmaen2026-11-14TransMedics' Q3: Revenue up 41%, but opex growth squeezes margins and EPShttps://compepharma.com/insights/2026-11-14-xenetic-s-all-stock-santersus-deal-shows-how-small-cap-biotechs-are-trading-equiCompePharmaen2026-11-14Xenetic's all-stock Santersus deal shows how small-cap biotechs are trading equity for assetshttps://compepharma.com/insights/2026-11-14-view-the-second-act-is-where-this-quarter-s-money-was-madeCompePharmaen2026-11-14The second act is where this quarter's money was madehttps://compepharma.com/insights/2026-11-14-macrogenics-funds-mgc026-through-2028-by-selling-assets-and-royalties-not-equityCompePharmaen2026-11-14MacroGenics Funds MGC026 Through 2028 by Selling Assets and Royalties, Not Equityhttps://compepharma.com/insights/2026-11-14-united-therapeutics-q3-tyvaso-dpi-lifts-sales-4-but-a-130m-r-d-charge-cuts-net-iCompePharmaen2026-11-14United Therapeutics Q3: Tyvaso DPI lifts sales 4%, but a $130M R&D charge cuts net income 24%https://compepharma.com/insights/2026-11-13-view-a-fee-schedule-rate-is-not-a-durable-price-coverage-is-the-real-assetCompePharmaen2026-11-13A fee schedule rate is not a durable price: coverage is the real assethttps://compepharma.com/insights/2026-11-13-collegium-s-q3-adhd-growth-and-azstarys-offset-a-pain-decline-but-profit-fallsCompePharmaen2026-11-13Collegium's Q3: ADHD growth and AZSTARYS offset a pain decline, but profit fallshttps://compepharma.com/insights/2026-11-13-cma-narrows-akzonobel-axalta-concerns-to-uk-refinish-testing-a-one-remedy-playboCompePharmaen2026-11-13CMA narrows AkzoNobel-Axalta concerns to UK refinish, testing a one-remedy playbookhttps://compepharma.com/insights/2026-11-13-view-plan-the-exit-before-the-readout-strategic-alternatives-shouldn-t-start-after-aCompePharmaen2026-11-13Plan the exit before the readout: strategic alternatives shouldn't start after a misshttps://compepharma.com/insights/2026-11-13-theriva-s-350-000-syn-004-sale-shows-how-small-biotechs-are-pruning-to-a-singleCompePharmaen2026-11-13Theriva's $350,000 SYN-004 sale shows how small biotechs are pruning to a single bethttps://compepharma.com/insights/2026-11-13-irhythm-s-q3-volume-led-growth-and-23-1-adjusted-ebitda-margin-masked-by-a-49-8mCompePharmaen2026-11-13iRhythm's Q3: Volume-led growth and 23.1% adjusted EBITDA margin, masked by a $49.8M litigation chargehttps://compepharma.com/insights/2026-11-13-merck-kgaa-s-pending-silence-deal-lands-as-divesiran-data-de-risk-an-rnai-assetCompePharmaen2026-11-13Merck KGaA's pending Silence deal lands as divesiran data de-risk an RNAi assethttps://compepharma.com/insights/2026-11-13-view-evidence-or-revenue-biotech-s-middle-ground-is-where-deals-go-to-dieCompePharmaen2026-11-13Evidence or revenue: biotech's middle ground is where deals go to diehttps://compepharma.com/insights/2026-11-13-longeveron-s-elpis-ii-miss-opens-a-sale-or-merge-review-as-biotech-deal-value-spCompePharmaen2026-11-13Longeveron's ELPIS II miss opens a sale-or-merge review as biotech deal value splitshttps://compepharma.com/insights/2026-11-13-obsidian-s-first-quarter-as-a-public-company-324-4m-cash-a-widening-loss-and-a-2CompePharmaen2026-11-13Obsidian's first quarter as a public company: $324.4M cash, a widening loss and a 2027 readouthttps://compepharma.com/insights/2026-11-12-view-this-season-rewards-companies-that-can-fund-their-own-ambitionCompePharmaen2026-11-12This season rewards companies that can fund their own ambitionhttps://compepharma.com/insights/2026-11-12-tarsus-s-xdemvy-hits-194-6m-as-632-2m-of-acquired-ipr-d-drives-a-668-3m-lossCompePharmaen2026-11-12Tarsus's XDEMVY hits $194.6M as $632.2M of acquired IPR&D drives a $668.3M losshttps://compepharma.com/insights/2026-11-12-kiora-s-kio-401-in-license-shows-ophthalmology-deal-making-is-shifting-to-earlyCompePharmaen2026-11-12Kiora's KIO-401 In-License Shows Ophthalmology Deal-Making Is Shifting to Early, Asset-Light Betshttps://compepharma.com/insights/2026-11-12-view-sell-the-map-keep-the-compass-regional-licensing-is-biotech-s-smartest-small-deaCompePharmaen2026-11-12Sell the map, keep the compass: regional licensing is biotech's smartest small dealhttps://compepharma.com/insights/2026-11-12-xeris-q3-recorlev-now-drives-the-story-as-the-company-lifts-2026-and-2030-revenuCompePharmaen2026-11-12Xeris Q3: Recorlev Now Drives the Story as the Company Lifts 2026 and 2030 Revenue Targetshttps://compepharma.com/insights/2026-11-12-view-compepharma-view-trust-the-raise-you-can-check-this-quarter-not-the-target-you-cCompePharmaen2026-11-12CompePharma View: Trust the raise you can check this quarter, not the target you can'thttps://compepharma.com/insights/2026-11-12-tg-therapeutics-lifts-2026-guidance-to-1b-as-briumvi-growth-meets-a-2027-28-dosiCompePharmaen2026-11-12TG Therapeutics lifts 2026 guidance to ~$1B as BRIUMVI growth meets a 2027–28 dosing pivot